3 Stocks Soaring Higher on These Drug Successes

The biotech space had several winners today, and in this segment from Wednesday's Market Checkup, Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof.

First up is Chelsea Therapeutics (NASDAQ: CHTP  ) , up a massive 20% on news that its drug Northera was finally approved. Despite the advisory committee's overwhelming support, the market was unsure if this would gain approval, but after delaying its decision from Friday until Tuesday, the FDA gave the thumbs-up.

Next is Furiex (UNKNOWN: FURX.DX  ) , which had seen shares skyrocket 130% on the news that its IBS drug had passed its phase 3 trial with flying colors, and has now announced that it is looking for a buyer. The market showed initial enthusiasm on the news that Furiex was for sale, but that sentiment has now cooled slightly, possibly on the realization that finding a buyer may be easier said than done, as the company's drug isn't without its safety issues.

And finally, Eli Lilly (NYSE: LLY  ) got the win it needed with its critical drug candidate ramucirumab, which showed strong results in a phase 3 trial as a second line non-small cell lung cancer treatment. The market reacted positively with shares climbing about 5%, as the drug achieved statistical significance both in progression-free survival and overall survival rates.

In the video, David tells investors what to expect from these drugs from here, and what he'll be watching for from these companies down the road.

How do savvy investors play the biotech game?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2845967, ~/Articles/ArticleHandler.aspx, 12/20/2014 5:27:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement